Herpes simplex virus vaccines
Herpes simplex virus vaccines
复制标题
DOI：
10.1016/s0264-410x(98)00434-4
复制
发表时间：
1999-03-26
期刊：
影响因子：
5.5
通讯作者：
Stanberry, LR
中科院分区：
文献类型：
--
作者：
Bernstein, DI;Stanberry, LR
单纯疱疹病毒(HSV)感染很常见，不仅会产生原发感染，还会产生潜伏性和复发性感染。因此，单纯疱疹病毒疫苗的目标与其他疫苗不同。在这篇综述中，我们讨论了预防和治疗HSV疫苗的目标，并与急性和复发HSV感染的免疫生物学相关。接下来，描述已经和正在评估的控制单纯疱疹病毒病的疫苗策略。目前的方法利用了许多现代疫苗开发方法。因此，在我们等待HSV糖蛋白亚单位疫苗的最终评估时，早期I期试验正在评估较新的疫苗方法，包括基于DNA的疫苗和复制受损的病毒。最终的单纯疱疹病毒疫苗可能会等待对最佳病毒抗原(S)和诱导生殖道免疫的途径的更多了解。(C)1999爱思唯尔科学有限公司。保留所有权利。
Herpes simplex virus (HSV) infections are common and produce not only a primary infection, but also latent and recurrent infections. Therefore, the goals of a HSV vaccine are different from other vaccines. In this review, the goals of both prophylactic and therapeutic HSV vaccines are discussed and related to the immunobiology of acute and recurrent HSV infections. Next, the vaccine strategies that have been and are being evaluated for control of HSV disease are described. Current approaches take advantage of many of the modern methodologies for vaccine development. Thus, as we await final evaluations of subunit HSV glycoprotein vaccines, early phase I trails are evaluating newer vaccine approaches including DNA-based vaccines and replication-impaired viruses. The definitive HSV vaccine may await increased knowledge of the optimal viral antigen(s) and routes to induce genital tract immunity. (C) 1999 Elsevier Science Ltd. All rights reserved.